Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Impedance Combination01:21

Impedance Combination

736
Consider a string of christmas lights, each bulb symbolizing an impedance element. In this series configuration, the flow of electric current remains uniform across every component. This behavior aligns with Kirchhoff's Voltage Law (KVL), which asserts that the total impedance in such a setup equals the sum of individual impedances—akin to resistors in series. It follows that the voltage from the power source is distributed proportionally among these components, adhering to the voltage...
736
Combination Of Resistors01:18

Combination Of Resistors

3.5K
Electrical devices in any circuit can be connected either by series or parallel connections. Additionally, circuits can be connected involving both of these connections, known as combination or complex circuits. As these circuits have complex resistor connections, it is necessary to identify different parts as either series or parallel connections, then the whole combination of series and parallel resistors can be reduced to a single equivalent resistance. With the known equivalent resistance...
3.5K
Stresses under Combined Loadings01:23

Stresses under Combined Loadings

467
When analyzing a bent tube with a circular cross-section subjected to multiple forces, it is crucial to determine the stress distribution in order to maintain structural integrity under varied load conditions.
The process begins by slicing the tube at critical points and analyzing the internal forces and stress components at these sections, focusing on the centroid. Normal stresses, generated by axial forces and bending moments, are either compressive or tensile and vary across the section from...
467
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

6.8K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
6.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Combined Effects of Drugs: Antagonism01:30

Combined Effects of Drugs: Antagonism

11.7K
The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
11.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Patients' Experiences of Nurse-Led Integrative Palliative Care in Multiple Myeloma.

Cancer nursing·2026
Same author

Daratumumab-Bortezomib-Cyclophosphamide-Dexamethasone in Newly Diagnosed Amyloidosis: ANDROMEDA Final Survival Analysis.

Blood·2026
Same author

MRD conversion during oral azacitidine maintenance correlates with outcomes in predominantly favorable-risk AML.

Annals of hematology·2026
Same author

Fixed-duration obinutuzumab-ibrutinib-venetoclax for Richter's transformation: results from the phase II GIVeRS trial.

Haematologica·2026
Same author

Viral Reactivation in Multiple Myeloma Patients Receiving Anti-BCMA Chimeric Antigen Receptor T-Cell Therapy.

International journal of molecular sciences·2026
Same author

Phase 1b study of ABBV-744, a novel, selective BET inhibitor, as monotherapy for patients with myelofibrosis.

Blood advances·2026

Related Experiment Video

Updated: Jan 26, 2026

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma
08:31

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma

Published on: September 12, 2025

791

Romidepsin-Bendamustine Combination for Relapsed/Refractory T Cell Lymphoma.

Boaz Nachmias1, Adir Shaulov1, David Lavie1

  • 1Department of Hematology, Hadassah - Hebrew University Medical Center, Jerusalem, Israel.

Acta Haematologica
|April 4, 2019
PubMed
Summary

The combination of romidepsin and bendamustine shows promise for treating relapsed/refractory peripheral T cell lymphoma (PTCL). This novel approach appears feasible with minimal toxicity, suggesting potential for improved patient outcomes.

Keywords:
BendamustineRomidepsinT cell lymphoma

More Related Videos

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma
15:07

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma

Published on: December 28, 2015

27.3K
Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

11.6K

Related Experiment Videos

Last Updated: Jan 26, 2026

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma
08:31

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma

Published on: September 12, 2025

791
VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma
15:07

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma

Published on: December 28, 2015

27.3K
Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

11.6K

Area of Science:

  • Oncology
  • Hematology
  • Pharmacology

Background:

  • Relapsed/refractory peripheral T cell lymphoma (PTCL) has limited treatment options.
  • Romidepsin, a histone deacetylase inhibitor, shows partial efficacy in R/R PTCL but can cause significant toxicity when combined with other chemotherapy.
  • There is a need for more effective and less toxic treatment strategies for R/R PTCL.

Purpose of the Study:

  • To evaluate the efficacy and safety of combining romidepsin with bendamustine in patients with R/R PTCL.
  • To determine if this combination can maximize therapeutic benefit while minimizing adverse events.

Main Methods:

  • A series of 7 heavily pretreated PTCL patients received the romidepsin-bendamustine combination.
  • Patients had received 2-5 prior lines of therapy.
  • The study observed treatment response, progression-free survival, and toxicity profiles.

Main Results:

  • Two of four patients with no prior exposure to either drug achieved complete remission.
  • One patient experienced over 4 years of progression-free survival.
  • Toxicity was minimal, with mild hematological toxicity and no treatment-related deaths or discontinuations. Nausea and vomiting were common.

Conclusions:

  • The romidepsin-bendamustine combination appears to be a feasible and potentially effective therapeutic option for R/R PTCL.
  • Further investigation in larger patient cohorts is warranted to confirm these findings.
  • This combination may offer a better efficacy-toxicity balance compared to other romidepsin-based regimens.